Featured Grant Funding
National Cancer Institute - Lymphoma SPORE ($ 12.5M)
The Leukemia & Lymphoma Society - Mantle Cell Lymphoma SCOR ($ 2.5M) (2018-2022) (L. Kwak)
- Project 1: A Novel CAR T Cell Therapy Targeting BAFF-R for Mantle Cell Lymphoma (L. Kwak, H. Qin)
- Project 2: Combining CAR T Cells With Signaling Modulators for Treatment of Relapsed/Refractory Mantle Cell Lymphoma (S. Forman, X. Wang, E. Budde)
- Project 3: Selective Targeting of Cyclin-dependent Kinase-9 (CDK9) for Treatment of Mantle Cell Lymphoma. (A. Danilov)
- Core A: Pathology and Tissue Bank Core (J. Chan, J. Song)
- Core B: Translational Core (S. Thomas, C. Matsumoto)
The Leukemia & Lymphoma Society - Influential Medicine Providing Access to Clinical Trials (IMPACT) Award (2022-2027)
Establishing Hematology Clinical Trial Hubs Within the City of Hope Community and Affiliate Network (T. Siddiqi)
National Cancer Institute - R01 grant (2021-2026)
R01 Overcoming Ibrutinib Resistance in Mantle Cell Lymphoma (A. Danilov)
National Cancer Institute - R01 grant (2019-2024)
Cutaneous T cell Lymphoma: A Paradigm for Dissecting Susceptibility and Resistance to Checkpoint Inhibition Therapy (C. Querfeld)
V Foundation - V Clinical Scholar Program (2021-2023)
Optimizing Immunotherapy for Hodgkin Lymphoma (A. Herrera)
The Leukemia & Lymphoma Society - Scholar in Clinical Research Award (2018-2023)
Unraveling the Mechanisms of Immune Checkpoint Dysfunction in Cutaneous T Cell Lymphoma (C. Querfeld)
The Leukemia & Lymphoma Society - Scholar in Clinical Research Award (2022-2027)
Stratified Treatment of Newly Diagnosed Mantle Cell Lymphoma Based on the Presence or Absence of High Risk Features Utilizing Non-cytotoxic Agents (T. Phillips)
National Cancer Institute - R01 Grant (2021-2026)
BAFF-R CAR T cell therapy for ALL (L. Kwak, X. Wang, I. Aldoss)
National Cancer Institute - U01 Grant (2021-2026)
Pre-analytical Variables of Bioanalytes Affecting the Accuracy of PTCL Diagnostic and Prognostic Genetic Signatures (J. Chan, J. Iqbal, M. Murtaza)